Healthcare Industry News: metabolic disease
News Release - March 19, 2010
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of DirectorsTOKYO, March 19 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE:4503.to ) today notified OSI Pharmaceuticals Inc. (Nasdaq:OSIP ) that John D. Gilly, Ph.D. and Margaret T. Monaco will replace Jack Kaye and Heidi L. Steiger on the slate of directors Astellas plans to nominate for election to OSI Pharmaceutical's board of directors at OSI's 2010 annual stockholders' meeting.
Astellas is committed to providing an independent voice for OSI stockholders who want its board of directors to consider Astellas' compelling $52 per share all-cash offer for OSI.
Dr. Gilly currently serves as an Associate Director in the Biopharmaceutical Development Program with SAIC-Frederick, Inc., at NCI-Frederick, Inc., a federally funded research and development center focused on oncology. Prior to joining SAIC-Frederick, Inc., he served as a director and Chief Operating Officer of Premier Research Group, plc, a U.K.-based publicly traded research organization that provides clinical trial services to biopharmaceutical and medical device companies, from 2006 through 2007, and as president of Premier Research Group's U.S. operations from 2002 through 2006.
Margaret T. Monaco is the Principal of Probus Advisors, a financial and strategic consulting firm. She currently sits on the board and is a member of the audit committee of Barnes & Noble, Inc. Ms. Monaco has also served as an independent director and member of the audit committee of W.P. Stewart & Co. Growth Fund, Inc. and is a former Chief Operating Officer of Merrill Lynch Ventures, LLC / KECALP Inc.
The highly qualified, full slate of independent directors proposed by Astellas is composed of Martin Edelshain, Cono R. Fusco, Michael A. Griffith, John D. Gilly, Jill Kanin-Lovers, Douglas E. Linton, Timothy P. Lynch, Jonathan R. Macey, Margaret T. Monaco and Joseph L. Turner.
Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.
Further details related to this proposal can be found on www.oncologyleader.com
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 14,200 employees worldwide. The organization is committed to becoming a global category leader in urology, immunology & infectious diseases, neuroscience, DM complications & metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en.
Important Additional Information
This communication is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell OSI Pharmaceuticals ("OSI") common stock. The tender offer (the "Tender Offer") is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc. (collectively, "Astellas") with the Securities and Exchange Commission ("SEC"). These materials, as they may be amended from time to time, contain important information, including the terms and conditions of the Tender Offer, that should be read carefully before any decision is made with respect to the Tender Offer. Investors and security holders may obtain a free copy of these materials and other documents filed by Astellas with the SEC at the website maintained by the SEC at www.sec.gov. The Offer to Purchase, Letter of Transmittal and other related Tender Offer materials may also be obtained for free by contacting the information agent for the Tender Offer, Georgeson Inc., at (212) 440-9800 for banks and brokers and at (800) 213-0473 for persons other than banks and brokers.
In connection with Astellas' proposal to nominate directors at OSI's annual meeting of stockholders, Astellas expects to file a proxy statement with the SEC. Investors and security holders of OSI are urged to read the proxy statement and other documents related to the solicitation of proxies filed with the SEC carefully in their entirety when they become available because they will contain important information. Stockholders of OSI and other interested parties may obtain, free of charge, copies of the proxy statement (when available), and any other documents filed by Astellas with the SEC in connection with the proxy solicitation, at the SEC's website as described above. The proxy statement (when available) and these other documents may also be obtained free of charge by contacting Georgeson Inc. at the numbers listed above.
Astellas and certain of their directors and executive officers and the individuals to be nominated by Astellas for election to OSI's board of directors may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding these directors and executive officers and other individuals is available in the Schedule TO that was filed March 2, 2010, and other documents filed by Astellas with the SEC as described above. Further information will be available in any proxy statement or other relevant materials filed with the SEC in connection with the solicitation of proxies when they become available.
No assurance can be given that the proposed transaction described herein will be consummated by Astellas, or completed on the terms proposed or any particular schedule, that the proposed transaction will not incur delays in obtaining the regulatory, board or stockholder approvals required for such transaction, or that Astellas will realize the anticipated benefits of the proposed transaction.
Statement on Cautionary Factors
Any statements made in this communication that are not statements of historical fact, including statements about Astellas' beliefs and expectations and statements about Astellas' proposed acquisition of OSI, are forward-looking statements and should be evaluated as such. Forward-looking statements include statements that may relate to Astellas' plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. Factors that may materially affect such forward-looking statements include: Astellas' ability to successfully complete the tender offer for OSI's shares or realize the anticipated benefits of the transaction; delays in obtaining any approvals required for the transaction, or an inability to obtain them on the terms proposed or on the anticipated schedule; and the failure of any of the conditions to Astellas' tender offer to be satisfied.
Any information regarding OSI contained herein has been taken from, or is based upon, publicly available information. Although Astellas does not have any information that would indicate that any information contained herein is inaccurate or incomplete, Astellas has not had the opportunity to verify any such information and does not undertake any responsibility for the accuracy or completeness of such information.
Astellas does not undertake, and specifically disclaims, any obligation or responsibility to update or amend any of the information above except as otherwise required by law.
Source: Astellas Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSeattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer